Table 2.
High GFR Non-Progressor (High-NP) and Progressors (High-P) transplants comparison by univariate (A) and multivariate (B) analyses
| A. | ||||
|---|---|---|---|---|
| High-NP | High-P | P-value | ||
| # Patients | 553 | 122 | ||
| # Serum Creatinine / patient | 35.2 ± 27.4 | 49.7 ± 32.2 | <0.0001 | |
| Slope of line | 1.4 ± 4.7% | −16 ± 10.2% | <0.0001 | |
| Graft loss (death-censored) | 1% (n7) | 34% (n41) | <0.0001 | |
| Graft failure <5 yrs | 1 | 36 | ||
| Graft failure >5 yrs | 6 | 5 | ||
| Mean follow-up (days) | 2525 ± 627 | 2069 ± 626 | <0.001 | |
| Range of follow-up (days) | [1075 – 3879] | [968 – 3897] | ||
| Demographics | ||||
| Recipient age at transplant | 51.9 ± 13.9 | 48.9 ± 14.2 | 0.0381 | |
| Donor age at transplant | 40.1 ± 12.6 | 41 ± 12.8 | 0.3433 | |
| Total # transplants | 1.1 ± 0.4 | 1.3 ± 0.6 | <0.0001 | |
| Recipient race (%caucasian) | 93% (n510) | 98% (n118) | 0.0477 | |
| Recipient gender (% female) | 37% (n207) | 48% (n58) | 0.0241 | |
| Donor type (% deceased) | 21% (n118) | 20% (n24) | 0.6809 | |
| % HLA A-B-DR identical | 8% (n45) | 7% (n9) | 0.7773 | |
| Pre-1 year data | ||||
| Induction (% Thymoglobulin) | 84% (n466) | 75% (n91) | 0.0274 | |
| Primary Immunosup (%CI) | 78% (n429) | 77% (n94) | 0.6743 | |
| Pre-transplant DSA+ | 12% (n39/339) | 21% (n13/63) | 0.0606 | |
| Class I+ | 7% (n23) | 8% (n5) | 0.7456 | |
| Class II+ | 8% (n26) | 16% (n10) | 0.0515 | |
| ≤1 year BK+ | 4% (n23) | 2% (n2) | 0.1435 | |
| ≤1 year Recurrent disease | 4% (n20) | 7% (n9) | 0.0837 | |
| ≤1 year Post-txp DSA+ | 7% (n6/87) | 15% (n3/20) | 0.2368 | |
| ≤1 year Non-protocol biopsy | 23% (n125) | 24% (n29) | 0.9685 | |
| 1 year data | ||||
| eGFRMDRD | 56.5 ± 10.9 | 56.6 ± 11.3 | 0.9530 | |
| 24-hr urine protein (% >150 mg) | 37% (n155) | 42% (n37) | 0.3438 | |
| Tacrolimus level | 8.6 ± 3.3 (86%) | 7.9 ± 2.6 (86%) | 0.0654 | |
| Histology | ||||
| Normal (cg, i, ci = 0) | 52% (n226) | 49% (n44) | 0.6577 | |
| IF alone (ci>0, i & cg=0) | 37% (n162) | 29% (n26) | 0.2253 | |
| IF+I (ci & i>0, cg=0) | 8% (n37) | 13% (n12) | 0.1619 | |
| Txp Glomerulopathy (cg>0) | 3% (n11) | 9% (n8) | 0.0346 | |
| Last Lab value (<1 yr from last eGFR) | ||||
| Tacrolimus level | 6.8 ± 2.7 (86%) | 7 ± 3.1 (88%) | 0.4512 | |
| 24-hr urine protein (% >150 mg) | 30% (n112) | 66% (n49) | <0.0001 | |
| DSA CI+ | 7% (n17) | 9% (n4) | 0.5980 | |
| DSA CII+ | 16% (n39) | 27% (n12) | 0.0728 | |
| B. | ||||||||
|---|---|---|---|---|---|---|---|---|
| Proportion of High-P grafts |
Univariate analysis | Multivariate analysis | ||||||
| Variable |
WITH variable |
WITHOUT variable |
Odds ratio |
CI 95% | P-value | Odds ratio |
CI 95% | P-value |
| Txp Glomerulopathy (cg>0) | 42% (n8/19) | 16% (n83/516) | 3.00 | 1.09 – 7.69 | 0.0346 | 2.05 | 0.4 – 9.41 | 0.3751 |
| Recipient age at transplant | - | - | 0.99 | 0.97 – 1 | 0.0381 | 0.99 | 0.97 – 1.02 | 0.6094 |
| Total # transplants | - | - | 2.27 | 1.51 – 3.41 | <0.0001 | 4.39 | 2.18 – 9.03 | <0.0001 |
| Recipient race (%caucausian) | 19% (n118/628) | 8% (n3/40) | 2.85 | 1.01 – 11.96 | 0.0477 | 1.88 | 0.42 – 13.6 | 0.4346 |
| Recipient gender (% female) | 22% (n58/265) | 16% (n64/410) | 1.58 | 1.06 – 2.23 | 0.0241 | 2.91 | 1.53 – 5.64 | 0.001 |
| Induction (% Thymoglobulin) | 16% (n91/557) | 26% (n31/118) | 0.58 | 0.37 – 0.94 | 0.0274 | 0.36 | 0.17 – 0.75 | 0.0068 |
| Pre-transplant DSA+ | 25% (n13/52) | 14% (n50/350) | 2.00 | 0.97 – 3.93 | 0.0606 | - | ||
| Pre-transplant DSA+Class II+ | 28% (n10/36) | 14% (n53/366) | 2.27 | 0.99 – 4.86 | 0.0515 | - | ||
| Last Lab value (<1 yr from last eGFR) | ||||||||
| 24-hr urine protein (% >150 mg) | 30% (n49/161) | 9% (n25/285) | 4.55 | 2.7 – 7.83 | <0.0001 | 4.24 | 2.27 – 8.08 | <0.0001 |
| DSA+Class II+ | 24% (n12/51) | 13% (n32/243) | 2.03 | 0.93 – 4.2 | 0.0728 | - | ||
Abbreviations: DSA = Donor Specific Antibody; IF = Interstitial Fibrosis; IF+I = Interstitial Fibrosis with Inflammation; DSA CI = DSA against Class I MHC, DSA CII = DSA against Class II MHC.